A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Summary

This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary antitumor activity and immunogenicity of 8MW2311 administered by intravenous (IV) infusion.

Timeline

Start

2022-08-05

Primary completion

2026-03

Completion

2026-03

Outcome

Outcome not reported

Stopped (Business): “Sponsor development strategy adjustment”

Drugs

Indications